Status:
COMPLETED
Using Intensity-Modulated Radiation Therapy to Permit Sparing of Parotid Gland Function
Lead Sponsor:
AHS Cancer Control Alberta
Conditions:
Head and Neck Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
PHASE2
Brief Summary
Radiotherapy is the primary treatment modality or an important adjunct treatment for many patients with H\&N carcinoma. Local control is directly related to dose and to the technical accuracy with whi...
Detailed Description
Radiotherapy is the primary treatment modality or an important adjunct treatment for many patients with H\&N carcinoma. Local control is directly related to dose and to the technical accuracy with whi...
Eligibility Criteria
Inclusion
- Squamous cell cancer of head and neck for radical/postoperative radiation therapy
- American Joint Committee on Cancer (AJCC) stage I-IV with M0 and N0-2 disease
- Karnofsky performance status (KPS) \>= 70%
Exclusion
- M1 or N3 disease
- Ineligibility for radiotherapy
- Recent malignancy
- Previous cancer or head and neck radiotherapy
- Salivary gland dysfunction
- Unwilling to provide informed consent
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00137475
Start Date
February 1 2002
End Date
August 1 2012
Last Update
February 26 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Cross Cancer Institute
Edmonton, Alberta, Canada, T6G 1Z2